Interfer(on)-ing in Melanoma
نویسندگان
چکیده
منابع مشابه
Adjuvant interferon for melanoma.
In their recent review, Punt and Eggermont [1] state that “combined data from low-dose IFN-α [interferon-α] trials does not suggest a benefit in ... DFS [disease-free survival]”. This conclusion is inconsistent with the results of a metaanalysis of these trials [2]. It is surprising that Punt and Eggermont [1] do not mention this study, especially as the latter was an author on the meta-analysi...
متن کاملAdjuvant interferon alfa for melanoma.
The author poses the question “Why did these study results not lead to a global consensus about interferon treatment as standard of care?” The answer is quite simple: The E1684 adjuvant high-dose interferon (hdifn) trial, while initially positive, was later shown to be negative. Remarkably, in spite of a p value of 0.09, the principal investigator still interpreted the trial as positive 1. Canc...
متن کاملInterferon system defects in human malignant melanoma.
We have examined the ability of melanoma cell lines and normal human melanocytes, which have demonstrable intact IFN genes, to secrete both IFN-alpha and IFN-beta in response to induction with virus. Normal melanocytes were found to secrete both IFN-alpha and IFN-beta after virus induction. In contrast, although all but one of the melanoma lines tested were capable of secreting IFN-beta, none w...
متن کاملAn update on adjuvant interferon for melanoma.
BACKGROUND Despite advances in the staging and surgical therapy of melanoma, patients with high-risk resected melanoma still have 5-year recurrence rates of 55% to 80% and 5-year survival rates as low as 25% to 70%. Effective adjuvant therapy is needed for this patient population. METHODS The authors review the literature regarding the use of interferon for the adjuvant therapy of resected me...
متن کاملCost effectiveness of adjuvant interferon in node-positive melanoma.
PURPOSE To assess the benefits of adjuvant high-dose interferon alfa (HDI) treatment for patients with high-risk melanoma. METHODS We designed a decision-analytic probabilistic Markov model to simulate the natural history of patients with stage IIIA, IIIB, and IIIC melanoma and evaluate the outcomes with and without HDI treatment. Outcomes were in quality-adjusted life years (QALYs) and incre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Science
سال: 2011
ISSN: 0036-8075,1095-9203
DOI: 10.1126/science.331.6020.988-d